Analyzing BioStem Technologies (OTCMKTS:BSEM) & Enlivex Therapeutics (NASDAQ:ENLV)

BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioStem Technologies and Enlivex Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioStem Technologies	0	1	0	1	3.00
Enlivex Therapeutics	1	1	1	1	2.50

BioStem Technologies currently has a consensus price target of $9.00, indicating a potential upside of 154.24%. Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 16,736.73%. Given Enlivex Therapeutics’ higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than BioStem Technologies.

Profitability

This table compares BioStem Technologies and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioStem Technologies	N/A	N/A	N/A
Enlivex Therapeutics	N/A	248.08%	206.39%

Institutional and Insider Ownership

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BioStem Technologies and Enlivex Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioStem Technologies	$292.21 million	0.22	-$28.56 million	($1.60)	-2.21
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.18

Enlivex Therapeutics has lower revenue, but higher earnings than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BioStem Technologies has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Summary

Enlivex Therapeutics beats BioStem Technologies on 9 of the 12 factors compared between the two stocks.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.